Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05064553 · ClinicalTrials.gov registry record
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
A clinical trial of Hepatocellular Carcinoma and Liver Cancer, sponsored by Exact Sciences Corporation.
- Active
- Registry status
- 2,990
- Enrollment target
- 20
- Study locations
NCT05064553: Active study of Hepatocellular Carcinoma and Liver Cancer, sponsored by Exact Sciences Corporation.
NCT05064553 is a study of Hepatocellular Carcinoma and Liver Cancer that is active but no longer recruiting, run by Exact Sciences Corporation. The registered enrollment target is 2,990 participants, above the 237-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (1162% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05064553, a study of Hepatocellular Carcinoma and Liver Cancer, is active but no longer recruiting, sponsored by Exact Sciences Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 2,990 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Conditions Studied
Interventions
- DEVICE Study CT/MRI Imaging
- DEVICE Standard of Care CT/MRI Imaging
- DIAGNOSTIC_TEST Oncoguard™ Liver Test
Study Locations (20)
California
- Franco Felizarta, MD - Bakersfield
- Gastroenterology & Liver Institute - Escondido
- Cedars Sinai Medical Center - Los Angeles
- Providence Facey Medical Foundation - Mission Hills
- United Medical Doctors - Murrieta
- VA Palo Alto Healthcare System - Palo Alto
- Stanford University Medical Center - Palo Alto
- California Liver Research Institute - Pasadena
- Cadena Care Institute - Poway
- Inland Empire Clinical Trials - Rialto
- Research & Education, Inc - San Diego
- San Jose Gastroenterology - San Jose
Florida
- University of Florida Hepatology Research at CTRB - Gainesville
- University of Florida - College of Medicine - Jacksonville
- ENCORE Borland Groover Clinical Research - Jacksonville
- Florida Research Institute - Lakewood
Arizona
- Arizona Health Research - Chandler
- Arizona Digestive Health - Sun City - Sun City
Colorado
- Rocky Mountain Gastroenterology - Littleton
District of Columbia
- Washington DC VA Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,990 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2026-12 |
What the registry record for NCT05064553 still lists
NCT05064553 is an observational study that tracks outcomes without assigning an intervention. Its 2,990 participants enrollment target places it among the larger protocols in the corpus, above the 237-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (1162% higher).
The record links to 5 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Study CT/MRI Imaging is the first listed.
NCT05064553 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05064553 about?
NCT05064553 is a clinical study titled "ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk". The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
What is the current status of trial NCT05064553?
This trial is currently active not recruiting. The enrollment target is 2,990 participants. The study started on 2021-07-26. Estimated completion is 2026-12.
What conditions does trial NCT05064553 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Cirrhosis, Hepatitis B, Hepatocellular Cancer.
What interventions are being tested in trial NCT05064553?
The interventions under investigation include: Study CT/MRI Imaging (DEVICE), Standard of Care CT/MRI Imaging (DEVICE), Oncoguard™ Liver Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05064553?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05064553 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05064553's enrollment target sits among peer trials
2,990 1st of 145 higher than 145 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05297734 · 2,996 participants · NA
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- NCT03860883 · 2,998 participants · NA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI